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Abstract
Background—The availability and diversity of lower limb revascularisation procedures have 
increased in England in the past decade. We investigated whether these developments in care
have translated to improvements in patient pathways and outcomes.
Methods—Individual-patient records from Hospital Episode Statistics (HES) were used to 
identify 103 934 patients who underwent endovascular (angioplasty) or surgical 
(endarterectomy, profundaplasty or bypass) lower limb revascularisation for infrainguinal 
peripheral artery disease (PAD) in England between January 2006 and December 2015. Major 
lower limb amputations and deaths within 1 year following revascularisation were ascertained 
from HES and Office for National Statistics mortality records. Competing risks regression was
used to estimate the cumulative incidence of major amputation and death, adjusted for patient 
age, sex, comorbidity score and indication for the intervention (intermittent claudication; severe 
limb ischaemia without tissue loss; severe limb ischaemia with ulceration; severe limb ischaemia 
with gangrene/osteomyelitis) and comorbid diabetes.
Results—The estimated 1-year risk of major amputation reduced from 5.7% (in 2006-07) to 
3.9% (in 2014-15) following endovascular revascularisation, and from 11.2% (2006-07) to 6.6% 
(2014-5) following surgical procedures. The risk of death after both types of revascularisation 
also reduced. These trends were observed for all indications categories, with the largest 
reductions found in patients with severe limb ischaemia with ulceration or gangrene. Overall, 
morbidity increased over the study period, and a larger proportion of patients were treated for the 
severe end of the PAD spectrum using less invasive procedures.
Conclusions—Our findings show that from 2006 to 2015, the overall survival increased and the 
risk of major lower limb amputation decreased following revascularisation. These observations
suggest that patient outcomes after lower limb revascularisation have improved during a period 
of centralisation and specialisation of vascular services in the United Kingdom.
Key Words: Revascularisation, endovascular, surgical, peripheral artery disease, PAD
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Clinical Perspective
What is new
x During a 10-year period from 2006 to 2015, the estimated 1-year risks of major 
amputation and death reduced after both endovascular and surgical lower limb 
revascularisation in England. 
x These trends were observed for all categories of peripheral artery disease severity, with 
the largest reductions seen among patients with the most severe underlying disease. 
x Overall, morbidity increased over the study period, and a larger proportion of patients 
were treated for the severe end of the PAD spectrum using less invasive revascularisation 
procedures.
What are the clinical implications
x Our findings show that patient outcomes after lower limb revascularisation have 
improved between 2006 and 2015. 
x These encouraging trends coincide with a period of centralisation and specialisation of 
vascular services in England, thought the findings cannot be interpreted as resulting 
directly from the reconfiguration of services. 
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Introduction
Mortality and amputation rates among patients undergoing endovascular or surgical 
revascularisation for lower limb peripheral artery disease (PAD) have been examined in 
randomised controlled trials and observational studies based on routinely collected 
hospitalisation data from the United States and Western European countries 1-7.  Over the past 
decades both types of studies have found high rates of both death and major lower limb 
amputation among revascularisation patients in the UK 1, 5, 6. For example, in a study based on 
hospital admission records, the investigators reported a 1-year amputation rate of 9.2% in and a 
1-year mortality rate of 16.1% after femoropoliteal bypass surgery performed in England in 
20066.  This has been a concern, particularly when compared to corresponding rates from other 
countries, such as Germany, Finland and different parts of the United States 2-4, 7.
The availability of revascularisation procedures has changed during the past decade 
(2006-2015), and with recent developments in endovascular and surgical technology, particularly 
stents and drug eluting technologies, less invasive procedures have become more widely used in 
the United Kingdom and elsewhere 8, 9. However, the impact of the increased availability and 
diversification of procedures on patient outcomes, such as major lower limb amputation and 
death, is unclear. For many patients both surgical and endovascular procedures are deemed 
suitable alternative revascularisation strategies and randomised controlled trials comparing the 
outcomes of these of procedures have aimed to produce information to guide clinical decision-
making where equipoise exists10, 11. In many cases, however, patient fitness or anatomy dictate 
that one treatment modality is preferable to the other. Patient selection will thus influence the 
patient outcomes after revascularisation procedures, which needs to be taken into account in 
analyses of routinely collected data.
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To investigate whether developments in care have translated to improvements in patient 
outcomes, we examined the 1-year risks of major lower limb amputation and death following
endovascular and surgical lower limb revascularisation for infrainguinal PAD undertaken 
between 2006 and in 2015 in England. Our analyses were based on individual-patient records
from a nationwide set of routinely collected hospital admissions data, Hospital Episode Statistics 
(HES).
Methods
Data sources
This study is exempt from United Kingdom National Research Ethics Committee approval as it 
involved secondary analysis of an existing dataset of anonymised data. HES data were made 
available by the NHS Digital (Copyright© 2015, reused with the permission of NHS Digital. All 
rights reserved). We do not have permission to share patient-level HES data and are therefore 
unable to make the data or study materials available to other researchers for replication purposes.
HES data are available from the NHS Digital Data Access Advisory Group 
(enquiries@nhsdigital.nhs.uk) for studies which meet the criteria for access to confidential data.
Individual-level data on endovascular and surgical lower limb revascularisations
performed between 1st January 2003 and 31st December 2015 were obtained from HES. This 
nationwide administrative dataset captures information on all hospital admissions in National 
Health Service (NHS) hospitals in England 12. Information on lower limb amputations following 
revascularisation was obtained from HES and mortality was ascertained by linking the patients’ 
HES records (using an encrypted individual identifiers) to Office for National Statistics (ONS) 
records of deaths registered in England up to the end of December 2015 13.
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Study population
Our study population was men and women, aged 35 years or older, who underwent their first
lower limb revascularisation for infrainguinal PAD (index procedure) during the ten-year period 
from January 2006 to December 2015. Patients with a HES record of a revascularisation up to 
three years prior to the index procedure (back to 2003) were excluded. We also excluded patients 
undergoing iliac procedures and those having revascularisation due to cancer or trauma. Patient 
records with missing data on covariates (patient demographics, indications for revascularisation 
or comorbidities) were also excluded (<1% of all potentially eligible patients).
Procedures and patient outcomes
The revascularisation procedures were divided into two groups: endovascular (angioplasty as the 
only revascularisation, with or without stent) and surgical revascularisations (endarterectomy or
profundaplasty as the only revascularisation, or leg bypass either as the only revascularisation or
in combination with other revascularisation procedures). Office for Population Censuses and 
Surveys (OPCS) version 4 codes used to identify these procedures are provided in Online 
Supplement 1, Tables S1 and S2.
The primary outcomes in our analyses were any major lower limb amputation and death 
from any cause occurring within one year of revascularisation. The OPCS codes for identifying 
major lower limb amputations are provided in Online Supplement 1, Table S3.
Patient characteristics
HES data included information on patient age, sex, comorbidities and indications for 
revascularisation. Indications and comorbidities were ascertained from the International 
Classification of Diseases version 10 (ICD-10) diagnostic codes recorded at the relevant 
admission. Indications for revascularisation were identified from the diagnostic codes recorded at 
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the index admission and defined as follows: IC: intermittent claudication; SLI1: severe limb 
ischaemia without a record of tissue loss; SLI2: severe limb ischaemia with ulceration; and SLI3:  
severe limb ischaemia with gangrene or osteomyelitis. Severe limb ischaemia was defined as 
PAD or diabetes with peripheral circulatory complications (Online Supplement, Table S4).
Comorbidities were coded into the Royal College of Surgeons (RCS) Charlson Score, as 
previously reported 14. Briefly, the score was defined as the number of selected comorbidities 
recorded at the index admission (revascularisation), with the exception of acute conditions (such 
as myocardial infarction), which were counted as co-morbidities if present in a HES record of a 
hospital admission within the 12 months prior to the index procedure. (Online Supplement, Table 
S5). PAD was used to define indication for intervention and thus not included in the RCS 
Charlson score. Comorbid diabetes was defined as a record of diabetes in the index admission or 
up to a year prior to it (Online Supplement, Table S6).
Statistical analyses
The risks of major amputation and death were examined using Fine-Gray competing risks 
regression. 15, 16 We examined unadjusted and multivariable-adjusted associations of each 
procedure with each outcome (amputation and death), with the other outcome as a competing 
risk. Analyses were stratified by diabetes status.  Linear, logistic and competing risks regression 
models were used to examine trends across the study period. The time-to-event was defined as 
months from the first revascularisation procedure to major lower limb amputation, death of the 
patient or the end of follow-up (one year after revascularisation). In the competing risk models 
the proportionality of sub-distribution hazards was checked by including an interaction term with 
time in the model. The assumption was valid for all procedure-outcome pairs. Age (ten-year 
bands), sex, the RCS Charlson score (0, 1, 2, 3+) and indications for revascularisation (IC, SLI1, 
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SLI2 and SLI3) were analysed as categorical variables and comorbid diabetes as a binary 
variable. The adjusted cumulative incidence rates are shown for the specified values of the main 
exposure, at average values of the covariates. All analyses were conducted using Stata MP 14
(Stata Corporation, College Station, Texas, US).
Results
The characteristics of the patients included in our analyses are summarised in Table 1. In total,
77 213 men and women underwent endovascular revascularisation and 26 721 underwent 
surgical revascularisation for infrainguinal PAD between January 2006 and December 2015. The 
median follow-up was 12 months (range: 5 days to 12 months). Most patients were men and the 
majority were aged 65 years or older. The age-distribution remained similar throughout the study 
period, whereas the proportion of men among revascularisation patients increased slightly from 
62.6% to 64.8%.  There was also an increase in the proportions of patients with RCS Charlson 
scores 2 and 3, as well as in the proportions of patients undergoing revascularisation for more 
severe limb ischaemia (SLI1, SLI2 and SLI3).  The prevalence of diabetes among the study 
population increased by approximately 8% over the study period. Overall, endovascular 
procedures became more common and surgical revascularisation less common over the study 
period. The proportions of patients who underwent an amputation or died during the year
following revascularisation decreased for both endovascular and surgical procedures.  (Table 1). 
Adjusted cumulative incidences of major lower limb amputation and death following 
endovascular and surgical revascularisation are shown in Figures 1 and 2, separately for each 
two-year interval. In the beginning of our study period, 2006-07, the 1-year cumulative incidence
of amputation was 5.7% after endovascular and 11.2% after surgical revascularisation (Figure 1). 
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By 2014-2015, the risk of amputation following endovascular procedures had reduced to 3.9%
(p<0.0001) and the same risk after surgery to 6.6% (p<0.0001). (Unadjusted estimates are 
provided in the Online Supplement, Figures S1 and S2, and Table S7.)
The adjusted 1-year cumulative incidence of death at the beginning of our study period, 
2006-07, was 9.5% following endovascular procedures and 11.1% following surgery. Both 
decreased during the following bi-yearly intervals, with the cumulative incidence of death in
2014-15 falling to 6.0% after endovascular and 6.4% after surgical revascularisation (p<0.0001)
(Figure 2).
Cumulative incidences of major amputation and death within one year of 
revascularisation, stratified by procedure and diabetes status, are shown in Figures 3 and 4. (The 
corresponding unadjusted estimates are provided in the Online Appendix, Tables S8 and S9.)
The cumulative incidence of each outcome was higher among diabetic patients than among 
patients with no record of diabetes, in both procedure groups and throughout the study period 
(Figures 3 and 4).
Figure 5 shows the secular change in the risks of amputation and death, by procedure and 
diabetes status. In addition to the risk estimates, sub-distribution hazard ratios (SHRs) are 
presented:  they indicate the change in the cumulative incidence functions for amputation and 
death during the bi-yearly intervals of follow-up compared to the baseline 2006-07. The 1-year 
cumulative incidence of major amputation following endovascular and surgical revascularisation 
reduced in diabetic and diabetes-free patients alike.  The cumulative incidence of death also 
reduced (Figure 5).
The cumulative incidences of amputation and death, by indication for revascularisation, 
are summarised in Figures 6 and 7, and shown in detail in the Online Appendix, Tables S10 and 
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S11. Compared to 2006-07, the 1-year cumulative incidence of amputation following 
endovascular revascularisation was lower in 2014-15 in all indication categories (Figure 6). The 
evidence for a decreasing trend was the most notable in patients undergoing surgical 
revascularisation for SLI2 or SLI3. In the first group, the cumulative incidence of amputation 
reduced from 19.5% to 69.5%, from 25.3% to 16.1%. The 1-year cumulative incidence of 
amputation after endovascular revascularisation showed a similar pattern, and the evidence for a 
decreasing trend in risk was again the clearest in the SLI2 and SLI3 groups (Figure 6 and Table 
S10). 
Cumulative incidence of death within a year following both endovascular and surgical 
revascularisation also decreased between the study baseline in 2006-07 and 2014-15, although 
the pattern was less clear than for amputation (Figure 7). Among patients undergoing 
endovascular revascularisation for IC or SLI1, the risk of death reduced by 2-3%, from 
approximately 6% to 3% in the IC group and 7% to 4% in the SLI1 group. Larger reductions 
were observed in the SLI2 and SLI3 groups, where the cumulative incidence of death decreased 
from 20.5% to 14.6% and from 25.5% to 15.9%, respectively (Figure 7 and Table S11). After 
surgical revascularisation, the 1-year cumulative incidence of death decreased from 
approximately 10% to 5% in the IC and SLI groups. Again, the reduction was more notable in
the SLI3 group (Figure 7 and Table S11).
The proportions of patients undergoing endovascular and surgical revascularisation, by 
year and indication for the intervention, are shown in Figure 8. Overall, the proportion of 
endovascular revascularisations increased and the proportion of surgical procedures decreased 
slightly over the study period (p<0.0001, Table 1 and Figure 8). The increasing trend was the 
clearest among patients undergoing revascularisation for SLI3: in this group, the proportion of 
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surgical revascularisations reduced from 33% in 2006-07 to 19% in 2014-2015 (p<0.0001).A 
similar trend was also observed in those treated for IC or SLI2. Among patients in the SLI1 
group, the split of the procedures (endovascular and surgical) varied across the study period but 
there was little evidence for a trend (p=0.06). Endovascular revascularisation also became more 
common and surgical procedures less common among patients with a record of diabetes, whereas 
among those with no diabetes, the proportions of the two types of procedures remained static 
(Online Supplement, Figure S3). 
Discussion
Summary of main findings 
Our findings suggest that during our study period, 2006-2015, the 1-year risk of major 
amputation in England reduced from 5.7% to 3.9% following endovascular and from 11.2% to 
6.6% following surgical lower limb revascularisation. The 1-year risk of death also reduced, 
from 9.5% to 6.0% following endovascular and from 11.1% to 6.4% following surgical 
procedures. The reduction in the risk of amputation was the largest among patients with most 
severe underlying disease (SLI3, severe limb ischaemia with gangrene).
We found some evidence that the relative frequency of the two types of revascularisation
procedures changed between 2006-07 and 2014-2015. Overall, endovascular revascularisation 
became more common over the study period. The evidence for this trend was the clearest among 
patients who were treated for SLI3 (severe limb ischaemia with gangrene). These observations 
reflect an increase in the overall number of endovascular procedures being performed over the 
study period, with the number of surgical procedures staying static. 
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Our investigation focused on 1-year risks of amputation and death following 
infrainguinal revascularisation, and the reducing 1-year risk of major amputation following 
revascularisation for infrainguinal PAD is in agreement with previous research findings. The 
BASIL trial and a previous study based on HES data, both with outcomes measured in the mid-
2000s, reported that approximately 12% of (mainly) femoropopliteal bypass patients underwent 
major amputation within a year of this operation. 1, 6 In our dataset 6.3% of patients undergoing 
endovascular and 11.9% of patients undergoing surgical revascularisation in 2006-07 had an 
amputation within a year of the index procedure. The slightly lower proportions of amputation 
outcomes in our analyses may be due to different inclusion and exclusion criteria: for instance, 
we excluded patients undergoing revascularisation due to cancer or trauma (ca. 2% of 
revascularisations in our dataset), which was not done in all previous studies. Our findings 
should not, however, be interpreted as indicative of the relative merits of endovascular and 
surgical revascularisation.
Several possible explanations for the observed reductions in the 1-year risk of amputation 
and death exist. One possibility is that the developments in techniques and technology (such as 
drug eluting stents) have led to more favourable patient outcomes.  Also, during our study 
period, in particular the years from 2010 to 2015, vascular services in the UK were subject to a 
process of specialisation away from general surgery, and centralisation from multiple low 
volume centres to a smaller number of high volume specialist centres. 17 It is possible that this 
reorganisation of vascular surgical care has had an impact on the changes and improvements 
identified in the current study. In response to increasing evidence pointing to a positive 
relationship between hospital and surgeon volumes and the outcome of arterial surgery18, in 2009 
the Vascular Society of Great Britain and Ireland (VSGBI) published recommendations on 
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reconfiguring the vascular services in the UK around a hub and spoke model. In this model of 
care all arterial surgery (including lower limb bypass and major amputations) is centralised into 
high-volume hub hospitals, with lower volume spoke hospitals providing local assessment, 
diagnosis and less complex interventions.  A hub is a hospital that provides a vascular on-call 
rota of 1:6 or greater, and serves a population-base of at least 800 000. 17, 19
Other possible explanations for the decreasing risks of amputation and death among PAD 
patients relate to changes in cardiovascular disease (CVD) epidemiology and risk factors in the 
years leading up to and during the study period, 2006-2015. For instance, the prevalence of 
smoking, an important risk factor for PAD, began to decrease in men and women in all age 
groups in the UK in the 1970s, and this trend has continued at least to the mid-2010s.20, 21 Co-
inciding with the reduction in smoking, prescription registers show that statin use increased in 
the UK in 1995-2013, in keeping with the National Institute of Health and Care Excellence 
(NICE) guidelines advising general practitioners (UK family physicians) to ensure statins are 
prescribed to all patients whose 10-year risk of CVD exceeds 20% (>10% since July 2014) 22, 23.
It is possible that the population-level reductions smoking exposure and cholesterol levels have 
led to the severity of PAD decreasing in patient cohorts presenting for revascularisation, which 
in turn could have improved outcomes of these procedures. However, our findings for 2006-2015
suggest that the overall proportion of patients having revascularisation for milder PAD (marked 
by IC) decreased and the proportions of those treated PAD with tissue loss increased. It seems 
thus unlikely that the observed improvements in outcomes reflect the decreasing severity of the 
underlying disease among patients undergoing revascularisation in the past few decades. 
Coinciding with the increase in statin use and decrease in smoking, the overall burden of 
CVD in the UK has declined since the 1970s 24.  Mortality and case-fatality from major CVD 
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outcomes (coronary heart disease and stroke) have declined considerably in all UK countries 24, 
25. The prevalence of CVD has, however, remained relatively static and slightly increased in men 
and women aged 65 years and older between 2004 and 2015, which Bhatnagar and colleagues 
hypothesise could be a result of the reduced mortality and case-fatality rates.25 Taken together, 
these trends suggest that the burden of CVD may be shifting from hard and fatal outcomes (e.g. 
myocardial infarction or stroke) to milder forms of the disease, such as PAD. If this is the case, 
patients who a few decades ago would have died of a major coronary event or stroke are now 
have their CHD is managed and are accessing health services for PAD. In this scenario, the 
findings of the present investigation would be even more encouraging, if indeed the outcomes 
were improving despite older and more severely ill patients with more (cardiovascular and other) 
comorbidities undergoing lower limb revascularisation. Our findings lend some support to this 
hypothesis, for although patient age remained static throughout the study period, the number of 
comorbidities and the severity of the underlying PAD appeared to increase. However, these 
interpretations warrant caution because improvements in the completeness and accuracy of 
diagnostic coding in HES may have influenced out findings.
Finally, the observation that the risks of amputation, as well as death, reduced steadily in
almost all patient groups could reflect an overall improvement in care, or it could relate to 
changes in clinical coding. A trend during our study period towards more complete and specific 
coding of secondary diagnoses (used to identify indications and comorbidities) could have led to 
overestimation of the risks of amputation and death during the earlier years in patients with the 
least severe underlying disease.  However, this seems to be an unlikely explanation for the 
observed results, as the falling risks were observed for the total patient cohort and were the 
largest among the most severely ill patients. Comparison to studies in other countries and 
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settings would help to assess whether our observations can be attributed to improvements in care, 
changes in CVD prevalence, incidence and risk factors, quality of the data, or some combination 
of all of these. 
Strengths and limitations
An important strength of our analyses is that we used a large set of routinely collected patient-
level data, which capture information on all revascularisation procedures conducted in NHS 
hospitals in England. It is thus unlikely that sample selection or loss to follow-up have 
significantly biased our findings. Furthermore, a dataset of just under 104 000 patients gave our 
analyses sufficient power to produce precise estimates of the risks of major lower limb 
amputation and death following endovascular and surgical revascularisation. A further strength 
of our analyses is that we used competing risks regression models to examine the risks of 
amputation and death separately, which is important for unpicking the associations of 
revascularisations with these outcomes in a population of older patients with multiple 
comorbidities.  The amount of missing data in our analyses was negligible (<1%).
A limitation in our study is that the diagnostic validity of HES for identifying indications 
for interventions and comorbid conditions is not ideal. However, a recent systematic review 
suggests that the accuracy of diagnostic coding in this dataset has improved since the mid- to late 
2000s 26, 27. Indeed, the reduction in the number of patients with no comorbidities (from 17% in 
2006-07 to 12% in 2014-2015, Table 1) could point to a larger number of comorbidities being 
accurately recorded in HES. It is possible that this contributed to some of the changes in 
outcomes and patient characteristics, such as the increasing prevalence of diabetes, observed 
over the study period. The coding of major interventions in HES is generally very accurate. 
Although it is possible that some revascularisation procedures have been incompletely recorded 
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or omitted from HES, which might have introduced bias to our estimates, we would expect the 
size of such bias to be small in comparison to the observed changes in risks.  
HES is a rich source of patient-level data on hospital admissions and procedures but it 
does not contain data on patient physiology or anatomy, and we were thus unable the gauge the 
potential confounding effects of patient fitness or vascular anatomy on the selection of patients 
for different types of revascularisation procedures. Finally, we conducted a large number of 
comparisons and it is therefore possible that some of the observed associations were chance 
findings.
Implications and future directions
Based on a large set of routinely collected observational data, the findings presented here should 
be interpreted as descriptive of the care and patient outcomes in England nationwide; further 
research, however, would be needed to produce risk models that would predict an individual 
patient’s risk of amputation or death associated with undergoing lower limb revascularisation. 
Large, well-conducted prospective studies, based on disease or procedure registers with detailed
information on physiological and anatomical covariates and linked to national hospitalisation and 
death records, would provide the best setting for future research into patient outcomes following 
lower limb revascularisation. They would provide generalisable information, with appropriate 
statistical power, to investigate the roles of the underlying disease and patient clinical 
characteristics on the patient care pathway and outcomes.
Conclusion
Over a 10-year period there has been a shift in the pattern of revascularisation procedures for 
infrainguinal PAD in England, with an increasing number of endovascular procedures being 
performed, especially among patients with the most severe forms of lower limb PAD. The 
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overall survival increased, and rate of major lower limb amputation decreased over the same 
period for both endovascular and surgical procedures, despite higher morbidity and larger 
proportions of patients treated for the severe end of the spectrum of PAD. These trends suggest 
overall improvements in the outcomes for patients with severe PAD during a period of 
centralisation and specialisation of vascular surgical services in the UK.
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Table 1. Participant characteristics by year of revascularisation
N (%) participants 2006-07 2008-09 2010-11 2012-13 2014-2015 p for trend 
across the 
study period
Procedures
Endovascular 13 701 (71.7) 14 826 (74.1) 16 117 (74.7) 16 922 (75.2) 15 647 (75.5) <0.0001
Surgical 5 402 (28.3) 5 190 (25.9) 5 470 (25.3) 5 582 (24.8) 5 077 (24.5)
Outcomes at 1 year
Amputation 1 514 (7.9) 1 535 (7.7) 1 542 (7.1) 1 504 (6.7) 1 370 (6.6) <0.0001
Death 2 362 (12.4) 2 330 (11.6) 2 486 (11.5) 2 426 (12.1) 2 143 (10.3) <0.0001
Covariates
Women 7 137 (37.4) 7 457 (37.3) 7 785 (36.1) 8 131 (36.1) 7 291 (35.2) <0.0001
Age (years)
<=49 688 (3.6) 718 (3.6) 857 (4.0) 810 (3.6) 763 (3.7) 0.4
50-59 2 252 (11.8) 2 392 (12.0) 2 618 (12.1) 2 870 (12.8) 2 676 (12.9)
60-69 4 904 (25.7) 5 066 (25.3) 5 541 (25.7) 5 634 (25.0) 5 052 (24.4)
70-79 6 426 (33.6) 6 557 (32.7) 6 812 (31.6) 7 052 (31.3) 6 469 (31.2)
80+ 4 833 (25.3) 5 283 (26.4) 5 759 (26.7) 6 38 (27.3) 3 764 (27.8)
RCS Charlson score
0 3 176 (16.6) 3 381 (16.9) 3 347 (15.5) 3 316 (14.7) 2 489 (12.0) <0.0001
1 11 166 (58.5) 10 949 (54.7) 11 119 (51.5) 11 227 (49.9) 9 978 (48.2)
2 1 549 (8.1) 1 825 (9.1) 2 160 (10.0) 2 289 (10.2) 4 109 (10.2)
3+ 3 212 (16.8) 3 861 (19.3) 4 961 (23.0) 5 672 (25.2) 6 148 (29.7)
Indication*
IC 5 760 (30.2) 5 212 (26.0) 4 509 (20.9) 3 721 (16.5) 3 104 (15.0) <0.0001
SLI1 9 104 (47.7) 10 039 (50.3) 11 290 (52.3) 12 303 (54.7) 11 341 (54.7)
SLI2 2 639 (13.8) 2 830 (14.1) 3 233 (15.0) 3 959 (17.6) 4 038 (19.5)
SLI3 1 600 (8.4) 1 905 (9.5) 2 555 (11.8) 2 521 (11.2) 2 241 (10.8)
Diabetic 4 977 (26.1) 5 426 (27.1) 6 255 (29.0) 7 130 (31.7) 7 210 (34.4) <0.0001
All 19 103 (100.0) 20 016 (100.0) 21 587 (100.0) 22 504 (100.0) 20 724 (100.0)
* IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; 
SLI3: severe limb ischaemia with gangrene/osteomyelitis
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Figure Legends
Figure 1. Multivariable-adjusted* cumulative incidence of amputation within 1 year following 
revascularisation †
* Adjusted for age, sex, RCS Charlson score and indication for revascularisation.  
† The figures show the cumulative incidence for the endovascular and surgical revascularisation, 
at mean values of covariates.
Figure 2. Multivariable-adjusted* cumulative incidence of death within 1 year following 
revascularisation †
* Adjusted for age, sex, RCS Charlson score and indication for revascularisation.  
†The figures show the cumulative incidence for the endovascular and surgical revascularisation, 
at mean values of covariates.
Figure 3. Multivariable-adjusted* cumulative incidence of amputation within 1 year following 
revascularisation, by type of procedure and comorbid diabetes
* Adjusted for age, sex, RCS Charlson score and indication for revascularisation. 
† E+D: endovascular, with diabetes; E-D: endovascular, no diabetes; S+D: surgical, with 
diabetes; S-D: surgical, no diabetes.  The figures show the cumulative incidence for the 
endovascular and surgical revascularisation, at mean values of covariates.
Figure 4. Multivariable-adjusted* cumulative incidence of death within 1 year following 
revascularisation, by type of procedure and comorbid diabetes
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* Adjusted for age, sex, RCS Charlson score and indication for revascularisation.
† Legend: E+D: endovascular, with diabetes; E-D: endovascular, no diabetes; S+D: surgical, 
with diabetes; S-D: surgical, no diabetes.   The figures show the cumulative incidence for the 
endovascular and surgical revascularisation, at mean values of covariates.
Figure 5. Secular change in the risk of amputation and death between 2006-07 and 2014-15, by 
procedure and diabetes status *
* Adjusted for age, sex, RCS Charlson score and indication for revascularisation.
Figure 6. Secular change in the risk of amputation between 2006-07 and 2014-15, by procedure 
and indication *
* adjusted for age, sex, RCS Charlson score and indication for revascularisation.
Figure 7. Secular change in the risk of death between 2006-07 and 2014-15, by procedure and 
indication *
* Adjusted for age, sex, RCS Charlson score and indication for revascularisation.
Figure 8. Proportions of patients undergoing endovascular and surgical revascularisation, by 
year and indication for revascularisation
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Supplemental Tables 
 
Table S1. Office of Population Censuses and Surveys Classification of Surgical Operations and 
Procedures (OPCS) version 4 codes to define endovascular lower limb revascularisation  
Code Description 
L63.1 Percutaneous transluminal angioplasty of femoral artery 
L63.5 Percutaneous transluminal insertion of stent into femoral artery 
L66.2 Percutaneous transluminal stent reconstruction of artery 
L66.5 Percutaneous transluminal balloon angioplasty of artery 
L66.7 Percutaneous transluminal placement of peripheral stent in artery 
L71.1 Percutaneous transluminal angioplasty of artery 
 
Table S2. OPCS version 4 codes to define surgical lower limb revascularisation  
Code Description 
Endarterectomy or profundaplasty 
L60.1 Endarterectomy of femoral artery and patch repair of femoral artery 
L60.2 Endarterectomy of femoral artery NEC 
L60.3 Profundaplasty of femoral artery and patch repair of deep femoral artery 
L60.4 Profundaplasty of femoral artery NEC 
Bypass 
L58.1 Emergency bypass of femoral artery by anastomosis of femoral artery to femoral 
artery NEC 
L58.2 Emergency bypass of femoral artery by anastomosis of femoral artery to popliteal 
artery using prosthesis NEC 
L58.3 Emergency bypass of femoral artery by anastomosis of femoral artery to popliteal 
artery using vein graft NEC 
L58.4 Emergency bypass of femoral artery by anastomosis of femoral artery to tibial artery 
using prosthesis NEC 
L58.5 Emergency bypass of femoral artery by anastomosis of femoral artery to tibial artery 
using vein graft NEC 
L58.6 Emergency bypass of femoral artery by anastomosis of femoral artery to peroneal 
artery using prosthesis NEC 
L58.7 Emergency bypass of femoral artery by anastomosis of femoral artery to peroneal 
artery using vein graft NEC 
L59.1 Bypass of femoral artery by anastomosis of femoral artery to femoral artery NEC 
L59.2 Bypass of femoral artery by anastomosis of femoral artery to popliteal artery using 
prosthesis NEC 
L59.3 Bypass of femoral artery by anastomosis of femoral artery to popliteal artery using 
vein graft NEC 
L59.4 Bypass of femoral artery by anastomosis of femoral artery to tibial artery using 
prosthesis NEC 
L59.5 Bypass of femoral artery by anastomosis of femoral artery to tibial artery using vein 
graft NEC 
L59.6 Bypass of femoral artery by anastomosis of femoral artery to peroneal artery using 
prosthesis NEC 
L59.7 Bypass of femoral artery by anastomosis of femoral artery to peroneal artery using 
vein graft NEC 
NEC: not elsewhere classified 
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Table S3. OPCS 4.6 codes to define major lower limb amputations 
Code Description 
X09.1 Hindquarter amputation 
X09.2 Disarticulation of hip 
X09.3 Amputation of leg above knee 
X09.4 Amputation of leg through knee 
X09.5 Amputation of leg below knee 
X09.8 Other specified amputation of leg 
X09.9 Unspecified amputation of leg 
 
Table S4. ICD-10 codes to define indications for revascularisation 
Disease/condition ICD-10 codes 
Intermittent claudication I739 
Severe limb ischaemia  
AND/OR 
Diabetes with peripheral  circulatory complications 
I702, I724, I730-8, I743-5, I771, 
I779 
E105, E115, E145 
Ulceration L97X, L030, L984 
Gangrene R02X 
Osteomyelitis M866, M869 
 
Table S5. ICD-10 codes to define co-morbidities included in the RCS Charlson score (from 
diagnosis codes in the record of the index admission and previous admissions) 
Co-morbidity ICD-10 codes 
Myocardial infarction I21*, I22*, I23*, I252 
Congestive cardiac failure I11, I13, I255, I42, I43, I50, I517 
Cerebrovascular disease G45, G46, I60–I69 
Dementia A810, F00–F03, F051, G30, G31 
Chronic pulmonary disease I26, I27, J40–J45, J46*, J47, J60–J67, J684, J701, J703 
Rheumatological disease  M05, M06, M09, M120, M315, M32–M36 
Liver disease B18, I85, I864, I982, K70, K71, K721, K729, K76, R162, 
Z944 
Hemiplegia or paraplegia G114, G81–G83 
Renal disease I12, I13, N01, N03, N05, N07, N08, N171*, N172*, N18, 
N19*, N25, Z49, Z940, Z992 
Any malignancy C00–C26, C30–C34, C37–C41, C43, C45–C58, C60–C76, 
C80–C85, C88, C90–C97 
Metastatic solid tumour  C77–C79 
AIDS/HIV infection  B20–B24 
AIDS: acquired immune deficiency syndrome; HIV: human immunodeficiency virus 
*Acute conditions that were defined as co-morbidities if present in a record of a previous hospital 
admission within 12 months prior to amputation.  
 
Table S6. Codes to define diabetes 
ICD-10 code  
E10 Insulin-dependent diabetes mellitus 
E11 Non-insulin-dependent diabetes mellitus 
E12 Malnutrition-related diabetes mellitus 
E13 Other specified diabetes mellitus 
E14 Unspecified diabetes mellitus 
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Table S7.  Associations of year with amputation and death within 1 year of revascularisation, stratified by procedure type 
Amputation  Unadjusted estimates Adjusted1 estimates  
Procedure 
Year 
N (%) 
amputations 
Cumulative 
incidence (%) 
SHR (95% CI)  p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Endovascular        
2006-07 870 (6.4) 6.3 1 (ref. cat)  5.7 1 (ref. cat)  
2008-09 977 (6.6)  6.4 1.04 (0.95, 1.14)  4.8 0.98 (0.89,1.07)  
2010-11 974 (6.0) 6.0 0 95 (0.87, 1.04)  4.1 0.81 (0.74, 0.89)  
2012-13 1 012 (6.0) 5.9 0.94 (0.86, 1.03)  3.9 0.76 (0.69, 0.83)  
2014-15 958 (6.1) 6.1 0.97 (0.88, 1.06) 0.1 3.9 0.76 (0.69, 0.83) <0.0001 
Surgical        
2006-07 644 (11.9) 11.9 1 (ref. cat)  11.2 1 (ref. cat)  
2008-09 558 (10.8) 9.1 0.90 (0.80, 1.00)  8.2 0.88 (0.79, 0.99)  
2010-11 568 (10.4) 8.9 0.86 (0.77, 0.97)  7.8 0.82 (0.73, 0.92)  
2012-13 492 (8.8) 7.8 0.73 (0.65, 0.82)  7.0 0.71 (0.63, 0.80)  
2014-15 412 (8.1) 7.3 0.67 (0.59, 0.76) <0.0001 6.6 0.66 (0.59, 0.75) <0.0001 
Death  Unadjusted estimates Adjusted1 estimates  
Procedure 
Year 
N (%)  
deaths 
Cumulative 
incidence (%) 
SHR (95% CI) p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Endovascular        
2006-07 1 630 (11.9) 11.9 1 (ref. cat)  9.5 1 (ref. cat)  
2008-09 1 718 (11.6) 11.3 0.97 (0.91, 1.04)  7.4 0.90 (0.84, 0.97)  
2010-11 1 849 (11.5) 11.2 0.96 (0.90, 1.03)  6.8 0.81 (0.76, 0.87)  
2012-13 2 048 (12.1) 11.6 1.02 (0.95, 1.08)  6.9 0.83 (0.78, 0.89)  
2014-15 1 643 (10.5) 10.5 0.88 (0.83, 0.95) 0.013 6.0 0.69 (0.64, 0.74) <0.0001 
Surgical        
2006-07 732 (13.6) 13.6 1 (ref. cat)  11.1 1 (ref. cat)  
2008-09 612 (11.8) 10.5 0.87 (0.78, 0.96)  7.8 0.83 (0.75, 0.93)  
2010-11 637 (11.7) 10.4 0.85 (0.76, 0.94)  7.4 0.77 (0.69, 0.86)  
2012-13 678 (12.2) 10.8 0.89 (0.81, 0.99)  7.7 0.81 (0.73, 0.91)  
2014-15 500 (9.9) 9.1 0.71 (0.64, 0.80) <0.0001 6.4 0.64 (0.57, 0.71) <0.0001 
1 Adjusted for age, sex, RCS Charlson score and indication for revascularisation.  
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Table S8.  Secular change in 1-year risk of major lower limb amputation, by procedure and diabetes status 
 
 
 
 
 Unadjusted estimates  Adjusted1 estimates 
Procedure 
Diabetes status 
Year N (%)  
amputations  
Cumulative 
incidence (%) 
SHR (95% CI) p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Endovascular         
Diabetes 2006-07 396 (10.7) 10.6 1 (ref. cat)  10.2 1 (ref. cat)  
 2008-09 481 (11.4) 10.9 1.08 (0.95, 1.24)  8.9 1.03 (0.90, 1.18)  
 2010-11 507 (10.3) 10.0 0.96 (0.85, 1.10)  7.7 0.85 (0.75, 0.97)  
 2012-13 556 (9.8) 9.6 0.91 (0.80, 1.04)  7.1 0.75 (0.66, 0.86)  
 2014-15 565 (9.8) 9.7 0.93 (0.81, 1.05) 0.019 7.1 0.76 (0.66, 0.86) <0.0001 
         
No diabetes 2006-07 474 (4.8) 4.7 1 (ref. cat)  4.1 1 (ref. cat)  
 2008-09 496 (4.7) 4.3 0.98 (0.87, 1.12)  3.2 0.93 (0.82, 1.06)  
 2010-11 467 (4.2) 3.8 0.88 (0.77, 1.00)  2.7 0.77 (0.67, 0.87)  
 2012-13 456 (4.1) 3.8 0.85 (0.75, 0.97)  2.6 0.74 (0.65, 0.84)  
 2014-15 393 (4.0) 3.7 0.83 (0.73, 0.96) 0.001 2.6 0.71 (0.62, 0.82) <0.0001 
         
Surgical         
Diabetes 2006-07 196 (15.5) 15.5 1 (ref. cat)  14.4 1 (ref. cat)  
 2008-09 164 (13.4) 10.8 0.86 (0.70, 1.05)  9.9 0.85 (0.69, 1.05)  
 2010-11 157 (11.9) 9.7 0.75 (0.60, 0.92)  8.8 0.73 (0.59, 0.90)  
 2012-13 159 (11.1) 9.3 0.70 (0.57, 0.86)  8.5 0.70 (0.56, 0.86)  
 2014-15 134 (9.8) 8.4 0.61 (0.49, 0.77) <0.0001 7.8 0.62 (0.50, 0.78) <0.0001 
         
No diabetes 2006-07 448 (10.8) 10.8 1 (ref. cat)  10.2 1 (ref. cat)  
 2008-09 394 (9.9) 8.6 0.91 (0.80, 1.04)  7.8 0.89 (0.78, 1.02)  
 2010-11 411 (9.9) 8.6 0.91 (0.80, 1.04)  7.6 0.86 (0.75, 0.98)  
 2012-13 333 (8.0) 7.2 0.73 (0.63, 0.84)  6.5 0.71 (0.62, 0.82)  
 2014-15 278 (7.5) 6.8 0.68 (0.59, 0.79) <0.0001 6.2 0.68 (0.58, 0.79) <0.0001 
1 Adjusted for age, sex, RCS Charlson score and indication for revascularisation  
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Table S9.  Secular change in 1-year risk of death following revascularisation, by procedure and diabetes status 
   Unadjusted estimates  Adjusted1 estimates  
         
Procedure 
Diabetes status 
Year N (%)  
deaths  
Cumulative 
incidence (%) 
SHR (95% CI) p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Endovascular         
Diabetes 2006-07 527 (14.2) 14.2 1 (ref. cat)  12.8 1 (ref. cat)  
 2008-09 556 (13.2) 12.3 0.93 (0.82, 1.05)  9.2 0.87 (0.77, 0.98)  
 2010-11 606 (12.3) 11.6 0.86 (0.76, 0.96)  8.0 0.73 (0.65, 0.83)  
 2012-13 809 (14.2) 13.0 1.00 (0.89, 1.11)  8.7 0.81 (0.72, 0.91)  
 2014-15 681 (11.8) 11.5 0.84 (0.75, 0.94) 0.035 7.5 0.66 (0.58, 0.74) <0.0001 
         
No diabetes 2006-07 1 103 (11.0) 11.0 1 (ref. cat)  8.0 1 (ref. cat)  
 2008-09 1 162 (10.9) 10.7 1.00 (0.91, 1.07)  6.4 0.92 (0.85, 1.00)  
 2010-11 1 243 (11.1) 10.8 1.00 (0.93, 1.09)  6.1 0.85 (0.79, 0.93)  
 2012-13 1 239 (11.0) 10.8 1.00 (0.92, 1.08)  5.9 0.83 (0.76, 0.90)  
 2014-15 962 (9.7) 9.8 0.88 (0.80, 0.96) 0.017 5.2 0.70 (0.64, 0.77) <0.0001 
 
Surgical         
Diabetes 2006-07 173 (13.7) 13.6 1 (ref. cat)  12.0 1 (ref. cat)  
 2008-09 139 (11.4) 10.3 0.83 (0.66, 1.04)  7.9 0.79 (0.63, 0.99)  
 2010-11 178 (13.5) 11.8 0.99 (0.80, 1.21)  8.6 0.87 (0.71, 1.08)  
 2012-13 175 (12.3) 10.9 0.89 (0.72, 1.10)  7.9 0.77 (0.63, 0.96)  
 2014-15 129 (9.4) 8.9 0.68 (0.54, 0.85) 0.006 6.2 0.57 (0.45, 0.72) <0.0001 
         
No diabetes 2006-07 559 (13.5) 13.5 1 (ref. cat)  10.8 1 (ref. cat)  
 2008-09 473 (11.9) 10.6 0.88 (0.78, 0.99)  7.8 0.85 (0.75, 0.96)  
 2010-11 459 (11.1) 10.0 0.81 (0.71, 0.91)  7.0 0.74 (0.65, 0.84)  
 2012-13 503 (12.1) 10.7 0.89 (0.79, 1.00)  7.7 0.83 (0.74, 0.94)  
 2014-15 371 (10.0) 9.2 0.73 (0.64, 0.83) <0.0001 6.4 0.66 (0.58, 0.76) <0.0001 
SHR: sub-distribution hazard ratio; CI: confidence interval 
1 IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; SLI3: severe limb 
ischaemia with gangrene/osteomyelitis. 2 Adjusted for age, sex, RCS Charlson score and indication for revascularisation.  
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Table S10.  Secular change in 1-year risk of major lower limb amputation following revascularisation, by procedure and indication 
   Unadjusted estimates  Adjusted2 estimates  
         
Procedure 
Indication1 
Year N (%) 
amputations 
Cumulative  
incidence (%) 
SHR (95% CI)  p trend Cumulative 
incidence (%) 
SHR (95% CI)  p trend 
Endovascular         
IC 2006-07 142 (3.6) 3.6 1 (ref. cat)  3.2 1 (ref. cat)  
 2008-09 159 (4.3) 3.9 1.20 (0.96, 1.50)  3.3 1.16 (0.93, 1.46)  
 2010-11 115 (3.6) 3.4 1.00 (0.78, 1.28)  2.8 0.93 (0.73, 1.19)  
 2012-13 95 (3.5) 3.4 0.98 (0.76, 1.28)  2.8 0.93 (0.72, 1.20)  
 2014-15 46 (2.0) 2.1 0.57 (0.41, 0.79) 0.001 1.7 0.51 (0.36, 0.71) <0.0001 
         
SLI1 2006-07 266 (4.0) 4.0 1 (ref. cat)  3.9 1 (ref. cat)  
 2008-09 290 (3.9) 3.5 0.96 (0.82, 1.14)  3.1 0.94 (0.79, 1.11)  
 2010-11 242 (2.9) 2.7 0.72 (0.60, 0.85)  2.4 0.67 (0.60, 0.81)  
 2012-13 304 (3.4) 3.1 0.83 (0.71, 0.99)  2.8 0.78 (0.66, 0.92)  
 2014-15 316 (3.9) 3.5 0.96 (0.82, 1.14) 0.4 3.0 0.87 (0.74, 1.03) 0.034 
         
SLI2 2006-07 222 (11.0) 11.0 1 (ref. cat)  10.5 1 (ref. cat)  
 2008-09 212 (9.5) 8.0 0.85 (0.71, 1.03)  7.4 0.84 (0.70, 1.02)  
 2010-11 235 (9.0) 7.7 0.81 (0.67, 0.97)  7.2 0.80 (0.67, 0.96)  
 2012-13 266 (8.3) 7.3 0.74 (0.62, 0.88)  6.7 0.72 (0.61, 0.87)  
 2014-15 292 (8.7) 7.7 0.79 (0.66, 0.94) 0.004 6.9 0.74 (0.62, 0.88) <0.0001 
         
SLI3 2006-07 240 (22.3) 22.3 1 (ref. cat)  22.1 1 (ref. cat)  
 2008-09 316 (23.0) 19.9 1.03 (0.87, 1.22)  19.3 1.04 (0.88, 1.23)  
 2010-11 382 (20.1) 17.9 0.89 (0.76, 1.05)  17.4 0.89 (0.76, 1.05)  
 2012-13 347 (17.3) 15.9 0.75 (0.64, 0.89)  14.9 0.71 (0.61, 0.82)  
 2014-15 304 (16.7) 15.4 0.73 (0.61, 0.86) <0.0001 14.4 0.69 (0.58, 0.82) <0.0001 
SHR: sub-distribution hazard ratio; CI: confidence interval 
1 IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; SLI3: severe limb 
ischaemia with gangrene/osteomyelitis. 2 Adjusted for age, sex, RCS Charlson score and indication for revascularisation. 
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Table S10, continued.  Secular change in 1-year risk of amputation following revascularisation, by procedure and indication 
   Unadjusted estimates  Adjusted2 estimates 
      
Procedure 
Indication1 
Year N (%) 
amputations 
Cumulative 
incidence (%) 
SHR (95% CI) p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Surgical         
IC 2006-07 175 (9.9) 9.9 1 (ref. cat)  9.6 1 (ref. cat)  
 2008-09 119 (8.0) 6.2 0.80 (0.64, 1.01)  5.9 0.79 (0.63, 1.00)  
 2010-11 91 (7.2) 5.4 0.72 (0.56, 0.92)  5.4 0.71 (0.55, 0.92)  
 2012-13 45 (4.5) 3.7 0.44 90.32, 0.61)  3.6 0.45 (0.32, 0.62)  
 2014-15 50 (6.0) 4.7 0.59 (0.43, 0.80) <0.0001 4.5 0.59 (0.43, 0.80) <0.0001 
         
SLI1 2006-07 214 (8.6) 8.6 1 (ref. cat)  8.5 1 (ref. cat)  
 2008-09 220 (8.5) 7.6 0.98 (0.82, 1.19)  7.3 0.97 (0.80, 1.17)  
 2010-11 241 (8.2) 7.4 0.95 (0.79, 1.15)  7.1 0.94 (0.78, 1.13)  
 2012-13 235 (7.1) 6.6 0.81 (0.68, 0.98)  6.3 0.80 (0.67, 0.96)  
 2014-15 209 (6.6) 6.3 0.77 (0.63, 0.93) 0.001 6.1 0.76 (0.63, 0.92) <0.0001 
         
SLI2 2006-07 120 (19.3) 19.4 1 (ref. cat)  19.5 1 (ref. cat)  
 2008-09 92 (15.7) 12.1 0.79 (0.60, 1.04)  11.6 0.76 (0.58, 1.00)  
 2010-11 79 (12.8) 10.2 0.63 (0.47, 0.83)  9.8 0.61 (0.46, 0.81)  
 2012-13 103 (14.0) 11.1 0.70 (0.53, 0.90)  10.9 0.69 (0.53, 0.89)  
 2014-15 79 (11.9) 9.8 0.59 (0.44, 0.78) <0.0001 9.5 0.58 (0.43, 0.77) <0.0001 
         
SLI3 2006-07 135 (25.7) 25.6 1 (ref. cat)  25.3 1 (ref. cat)  
 2008-09 127 (23.9) 21.4 0.93 (0.73, 1.19)  21.4 0.94 (0.74, 1.20)  
 2010-11 157 (24.0) 21.5 0.93 (0.74, 1.16)  21.2 0.92 (0.73, 1.16)  
 2012-13 109 (21.0) 19.2 0.80 (0.62, 1.02)  19.2 0.81 (0.63, 1.04)  
 2014-15 74 (17.7) 16.5 0.66 (0.50, 0.88) 0.002 16.1 0.65 (0.49, 0.86) 0.002 
SHR: sub-distribution hazard ratio; CI: confidence interval 
1 IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; SLI3: severe limb 
ischaemia with gangrene/osteomyelitis. 2 Adjusted for age, sex, RCS Charlson score and indication for revascularisation. 
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Table S11.  Secular change in 1-year risk of death following revascularisation, by procedure and indication 
   Unadjusted estimates  Adjusted2 estimates 
      
Procedure 
Indication1 
Year N (%)  
deaths 
Cumulative 
incidence (%) 
SHR (95% CI)  p trend Cumulative 
incidence (%) 
SHR (95% CI)  p trend 
Endovascular         
IC 2006-07 327 (8.2) 8.2 1 (ref. cat)  5.9 1 (ref. cat)  
 2008-09 285 (7.6) 6.9 0.93 (0.79, 1.09)  4.4 0.89 (0.75, 1.04)  
 2010-11 243 (7.5) 6.7 0.91 (0.77, 1.08)  4.2 0.84 (0.71, 0.99)  
 2012-13 161 (5.9) 5.5 0.72 (0.59, 0.86)  3.4 0.64 (0.53, 0.78)  
 2014-15 143 (6.3) 5.8 0.77 (0.63, 0.93) <0.0001 3.4 0.66 (0.54, 0.80) <0.0001 
         
SLI1 2006-07 566 (8.6) 8.5 1 (ref. cat)  6.5 1 (ref. cat)  
 2008-09 571 (7.6) 6.9 0.89 (0.79, 1.00)  4.8 0.86 (0.76, 0.96)  
 2010-11 580 (6.9) 6.4 0.80 (0.72, 0.90)  4.4 0.77 (0.69, 0.87)  
 2012-13 724 (8.1) 7.3 0.94 (0.84, 1.05)  4.8 0.86 (0.77, 0.96)  
 2014-15 571 (7.0) 6.5 0.82 (0.73, 0.92) 0.015 4.1 0.70 (0.62, 0.79) <0.0001 
         
SLI2 2006-07 435 (21.6) 21.7 1 (ref. cat)  20.5 1 (ref. cat)  
 2008-09 498 (22.2) 20.4 1.02 (0.90, 1.16)  17.8 0.98 (0.86, 1.11)  
 2010-11 525 (20.1) 18.9 0.92 (0.81, 1.04)  16.0 0.85 (0.74, 0.96)  
 2012-13 705 (21.9) 20.2 1.01 (0.89, 1.13)  17.2 0.93 (0.82, 1.05)  
 2014-15 560 (16.6) 16.7 0.76 (0.69, 0.86) <0.0001 14.6 0.72 (0.64, 0.82) <0.0001 
         
SLI3 2006-07 302 (28.1) 28.4 1 (ref. cat)  25.5 1 (ref. cat)  
 2008-09 364 (26.5) 23.0 0.93 (0.80, 1.08)  20.0 0.92 (0.79, 1.07)  
 2010-11 501 (26.4) 22.8 0.91 (0.79, 1.05)  19.0 0.85 (0.73, 0.98)  
 2012-13 458 (22.9) 20.4 0.77 (0.67, 0.89)  17.9 0.77 (0.67, 0.89)  
 2014-15 369 (20.3) 18.8 0.69 (0.59, 0.80) <0.0001 15.9 0.66 (0.57, 0.77) <0.0001 
SHR: sub-distribution hazard ratio; CI: confidence interval 
1 IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; SLI3: severe limb 
ischaemia with gangrene/osteomyelitis. 2 Adjusted for age, sex and RCS Charlson score. 
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Table S11, continued.  Secular change in 1-year risk of death following revascularisation, by procedure and indication 
   Unadjusted estimates  Adjusted2 estimates 
      
Procedure 
Indication1 
Year N (%)  
deaths 
Cumulative 
incidence (%) 
SHR (95% CI) p trend Cumulative 
incidence (%) 
SHR (95% CI) p trend 
Surgical         
IC 2006-07 213 (12.0) 12.0 1 (ref. cat)  9.5 1 (ref. cat)  
 2008-09 144 (9.7) 8.6 0.80 (0.65, 0.99)  6.3 0.77 (0.63, 0.96)  
 2010-11 127 (10.0) 8.7 0.82 (0.66, 1.02)  6.1 0.75 (0.60, 0.94)  
 2012-13 94 (9.4) 8.3 0.77 (0.61, 0.99)  6.1 0.75 (0.59, 0.96)  
 2014-15 72 (8.6) 7.6 0.70 (0.53, 0.91) 0.006 4.9 0.60 (0.46, 0.79) <0.0001 
         
SLI1 2006-07 289 (11.6) 11.6 1 (ref. cat)  9.8 1 (ref. cat)  
 2008-09 251 (9.7) 8.3 0.83 (0.70, 0.98)  6.2 0.80 (0.67, 0.94)  
 2010-11 272 (9.3) 8.1 0.79 (0.67, 0.93)  5.8 0.71 (0.60, 0.84)  
 2012-13 332 (10.0) 8.6 0.85 (0.73, 1.00)  6.3 0.78 (0.67, 0.92)  
 2014-15 626 (8.3) 7.4 0.71 90.60, 0.83) 0.001 5.3 0.62 (0.52, 0.74) <0.0001 
         
SLI2 2006-07 116 (18.7) 18.8 1 (ref. cat)  16.4 1 (ref. cat)  
 2008-09 104 (17.8) 17.2 0.95 (0.73, 1.24)  14.7 0.95 (0.72, 1.24)  
 2010-11 112 (18.1) 17.3 0.95 (0.73, 1.23)  14.7 0.95 (0.73, 1.23)  
 2012-13 138 (18.8) 17.8 1.00 (0.78, 1.27)  14.8 0.96 (0.75, 1.23)  
 2014-15 108 (16.2) 16.0 0.86 (0.66, 1.11) 0.04 12.9 0.80 (0.61, 1.04) 0.1 
         
SLI3 2006-07 114 (21.7) 21.6 1 (ref. cat)  19.1 1 (ref. cat)  
 2008-09 113 (21.3) 19.3 0.98 (0.76, 1.27)  15.3 0.94 (0.72, 1.22)  
 2010-11 126 (19.2) 18.0 0.88 90.68, 1.14)  13.8 0.80 (0.62, 1.04)  
 2012-13 114 (22.0) 19.8 1.01 (0.78, 1.31)  14.1 0.84 (0.65, 1.10)  
 2014-15 58 (13.8) 13.5 0.61 (0.45, 0.84) 0.016 10.1 0.56 (0.41, 0.77) 0.001 
SHR: sub-distribution hazard ratio; CI: confidence interval 
1 IC: intermittent claudication; SLI1: severe limb ischaemia without tissue loss; SLI2: severe limb ischaemia with ulceration; SLI3: severe limb 
ischaemia with gangrene/osteomyelitis. 2 Adjusted for age, sex and RCS Charlson score 
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Supplemental Figures 
 
Figure S1. Unadjusted cumulative incidence of amputation within 1 year following 
revascularisation 
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Figure S2. Unadjusted cumulative incidence of death within 1 year following revascularisation 
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Figure S3. Proportions of patients undergoing endovascular and surgical revascularisation, by 
year and diabetes status 
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